MicroRNAs Regulated Brain Tumor Cell Phenotype and Their Therapeutic Potential

Chengqi Zhang, Budong Chen, Xiangying Xu, Baolin Han, Guangshun Wang, Jinhuan WangInTech 2013 · DOI · OpenAlex

Abstract

MicroRNAs (miRNAs) are short 18–25 nucleotide small non-coding RNA molecules that function to silence gene expression via sophisticated post-transcriptional regulation. Since their discovery in the early 1990s, these small molecules have been shown to play an important regulatory role in a wide range of biological and pathological processes. Over 30% of human messenger RNAs (mRNAs) are regulated by miRNAs. miRNAs generated by the canonical biogenesis pathway are transcribed as precursor RNAs from intergenic, intronic, or polycistronic genomic loci by RNA polymerase II (Pol II). The primary miRNA (pri-miRNA) transcript forms a stem–loop structure processed by the Drosha and DGCR8 RNase III complex in the nucleus. The resulting pre-miRNA hairpins are transported to the cytosol by Exportin 5, where they are further processed by the Dicer and TRBP complex to form mature ~22-nucleotide miRNAs that associate with Argonaute proteins (e.g., AGO2).

Introduction: The Hidden Hand in Brain Tumors

Brain tumors, particularly glioblastoma multiforme (GBM), remain among the most lethal and treatment-resistant cancers. Despite advances in surgery and radiotherapy, prognosis is often poor due to the highly invasive nature of tumor cells and the presence of "glioma stem cells" (GSCs) that drive recurrence. This paper identifies miRNAs as the "hidden hand" behind these phenotypes, regulating over 30% of human protein-coding genes. By identifying deregulated miRNAs, researchers can better understand why some tumors are more aggressive and how to disrupt the signaling networks that sustain them.

Overview of the miRNA biogenesis pathway and gene silencing mechanism.

Methodology and Data Sources

This review synthesizes findings from hundreds of primary studies using diverse methodologies:

  • Expression Profiling: High-throughput techniques like microarrays and qRT-PCR identify "miRNA signatures" that distinguish healthy brain tissue from various tumor types.
  • Functional Assays: In vitro experiments, including MTT assays for proliferation and Annexin V staining for apoptosis, determine the effects of miRNA modulation.
  • Epidemiological Context: Data from the Central Brain Tumor Registry of the United States (CBTRUS) provides context on the distribution of primary CNS tumors, noting that gliomas account for 31% of all tumors and 80% of malignant cases.

Key Insights: OncomiRs vs. Tumor Suppressors

miRNAs function through a duality of roles. Some, like miR-128 and miR-34a, act as tumor suppressors and are often lost in cancer. Others, termed "oncomiRs" (e.g., miR-21), are overexpressed and silence genes that would normally trigger cell death or stop the cell cycle. A critical insight is the role of miRNAs in maintaining the "stemness" of GSCs; for instance, the loss of miR-128 allows the Bmi-1 oncogene to go unchecked, promoting self-renewal and chemoresistance.

Experimental Results

The paper highlights several key findings regarding specific miRNA clusters:

  • miR-21: Consistently elevated in almost all brain tumor types, correlating with poor patient survival. Knocking it down leads to a significant increase in apoptosis.
  • miR-221/222: These clustered miRNAs target cell cycle inhibitors p27 and p57. Their overexpression effectively "cuts the brakes" on cell division.
Experimental data showing the effect of miR-221/222 on cell proliferation and cell cycle distribution.

In therapeutic models, the combination of miR-21 suppression and cytotoxic agents like S-TRAIL has shown the ability to completely eradicate tumors in mouse models within days, demonstrating the potential of miRNA-based sensitization.

Limitations and Future Outlook

While the therapeutic potential is high, significant hurdles remain:

  • Delivery: Transporting miRNA-based drugs across the blood-brain barrier (BBB) is a major engineering challenge.
  • Specificity: The multi-target nature of miRNAs increases the risk of off-target effects in healthy brain tissue.
  • Clinical Translation: Most current evidence is derived from in vitro or animal models. Future work will likely focus on miRNA modulation as an adjuvant therapy to sensitize aggressive tumors to standard treatments.

Summary updated

Abstract

MicroRNAs (miRNAs)are short 18–25 nucleotide small non-coding RNA molecules that function to silence gene expression via sophisticated post-transcriptional regulation[1]. Since their discovery in the early 1990s, these small molecules have been shown to play an important regulatory role in a wide range of biological and pathological processes. Over 30% of human messenger RNAs (mRNAs) are regulated by miRNAs[2]. miRNAs generated by the canonical biogenesis pathway are transcribed as precursor RNAs from intergenic, intronic or polycis‐ tronic genomic loci by RNA polymerase II (Pol II). The primary miRNA (pri-miRNA) transcript forms a stem–loop structure that is recognized and processed by the Drosha and DGCR8 RNase III complex or the spliceosome apparatus in the nucleus. In the non-canonical miRNA pathway, miRNAs are transcribed directly as endogenous short hairpin RNAs (endo-shRNAs) or derive directly through splicing from introns that can refold into hairpins (mirtrons). The trimmed precursor (pre-miRNA) hairpins from both canonical and non-canonical miRNA pathways are then transported by an exportin 5 and RAN-GTP-dependent process to the cytosol, where they are typically further processed by the Dicer and transactivation-response RNA-binding protein (TRBP) RNase III enzyme complex to form the mature double-stranded ~22-nucleotide miRNA. Argonaute proteins (for example, AGO2)
BibTeX
@inproceedings{zhang2013micrornas,
  author = {Chengqi Zhang and Budong Chen and Xiangying Xu and Baolin Han and Guangshun Wang and Jinhuan Wang},
  title = {{MicroRNAs Regulated Brain Tumor Cell Phenotype and Their Therapeutic Potential}},
  booktitle = {InTech},
  year = {2013},
  doi = {10.5772/52362},
}
Figure